Brown, Gordon D. http://orcid.org/0000-0002-0287-5383
Ballou, Elizabeth R.
Bates, Steven http://orcid.org/0000-0003-0489-5705
Bignell, Elaine M. http://orcid.org/0000-0001-7748-1920
Borman, Andrew M. http://orcid.org/0000-0003-0585-5721
Brand, Alexandra C. http://orcid.org/0000-0002-7381-131X
Brown, Alistair J. P. http://orcid.org/0000-0003-1406-4251
Coelho, Carolina
Cook, Peter C. http://orcid.org/0000-0002-5208-4985
Farrer, Rhys A. http://orcid.org/0000-0001-8456-7458
Govender, Nelesh P.
Gow, Neil A. R. http://orcid.org/0000-0002-2776-5850
Hope, William
Hoving, J. Claire
Dangarembizi, Rachael
Harrison, Thomas S.
Johnson, Elizabeth M. http://orcid.org/0000-0003-3100-6969
Mukaremera, Liliane
Ramsdale, Mark
Thornton, Christopher R. http://orcid.org/0000-0001-6213-3130
Usher, Jane
Warris, Adilia http://orcid.org/0000-0001-6586-3358
Wilson, Duncan
Article History
Accepted: 14 May 2024
First Online: 25 June 2024
Competing interests
: W.H. has received research funding from the FDA; research funding and personal fees from F2G and Pfizer; and personal fees from GSK, Mundipharma and Pulmocide. T.S.H. has received an investigator award to institution from Gilead Sciences and speaker fees from Gilead and Pfizer and serves on Advisory or Data Monitoring Boards for F2G and Mundipharma. A.W. has received consultancy fees from Gilead and Mundipharma and payment for educational events from Gilead and F2G. The other authors declare no conflicts of interest.